Olaparib: Phase III started - BioCentury.comHome > Week in Review > Clinical Status > Olaparib: Phase III startedOlaparib: Phase III startedAstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.Product: Olaparib (AZD2281, KU-0059436)OrganizationsAstraZeneca plcProductsAZD2281KU-0059436Molecular TargetsPoly(ADP-ribose) polymerase (PARP)
